Department of Emergency Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Psychopharmacology (Berl). 2013 Oct;229(4):665-71. doi: 10.1007/s00213-013-3127-4. Epub 2013 May 9.
Deliberate self-poisoning (DSP), the most common form of deliberate self-harm, is closely associated with suicide. Identifying risk factors of DSP is necessary for implementing prevention strategies.
This study aimed to evaluate the relationship between benzodiazepine (BZD) treatment in psychiatric outpatients and DSP cases at emergency departments (EDs).
We performed a retrospective nested case-control study of psychiatric patients receiving BZD therapy to evaluate the relationship between BZD use and the diagnosis of DSP at EDs using data from the nationwide Taiwan National Health Insurance Research Database.
Regression analysis yielded an odds ratio (OR) and 95 % confidence interval (95 % CI) indicating that the use of BZDs in psychiatric outpatients was significantly associated with DSP cases at EDs (OR = 4.46, 95 % CI = 3.59-5.53). Having a history of DSP, sleep disorders, anxiety disorders, schizophrenia, depression, or bipolar disorder was associated with a DSP diagnosis at EDs (OR = 13.27, 95 % CI = 8.28-21.29; OR = 5.04, 95 % CI = 4.25-5.98; OR = 3.95, 95 % CI = 3.32-4.70; OR = 7.80, 95 % CI = 5.28-11.52; OR = 15.20, 95 % CI = 12.22-18.91; and OR = 18.48, 95 % CI = 10.13-33.7, respectively). After adjusting for potential confounders, BZD use remained significantly associated with a subsequent DSP diagnosis (adjusted OR = 2.47, 95 % CI = 1.93-3.17). Patients taking higher average cumulative BZD doses were at greater risk of DSP.
Vigilant evaluation of the psychiatric status of patients prescribed with BZD therapy is critical for the prevention of DSP events at EDs.
蓄意自伤(DSP)是最常见的蓄意自伤形式,与自杀密切相关。识别 DSP 的风险因素对于实施预防策略是必要的。
本研究旨在评估精神科门诊患者使用苯二氮䓬类药物(BZD)治疗与急诊科(ED)DSP 病例之间的关系。
我们使用来自全国性的台湾全民健康保险研究数据库的数据,进行了一项精神科患者接受 BZD 治疗的回顾性嵌套病例对照研究,以评估 BZD 使用与 ED 中 DSP 诊断之间的关系。
回归分析得出比值比(OR)和 95%置信区间(95%CI),表明精神科门诊患者使用 BZD 与 ED 中 DSP 病例显著相关(OR=4.46,95%CI=3.59-5.53)。有 DSP 病史、睡眠障碍、焦虑障碍、精神分裂症、抑郁症或双相情感障碍与 ED 中 DSP 诊断相关(OR=13.27,95%CI=8.28-21.29;OR=5.04,95%CI=4.25-5.98;OR=3.95,95%CI=3.32-4.70;OR=7.80,95%CI=5.28-11.52;OR=15.20,95%CI=12.22-18.91;OR=18.48,95%CI=10.13-33.7)。在调整潜在混杂因素后,BZD 使用与随后的 DSP 诊断显著相关(调整后的 OR=2.47,95%CI=1.93-3.17)。服用较高平均累积 BZD 剂量的患者 DSP 风险更高。
对于预防 ED 中 DSP 事件,对接受 BZD 治疗的患者进行精神状态的仔细评估至关重要。